Managing Oral Mucosal AEs of Adjuvant Endocrine Therapy in Patients With Breast Cancer
A literature review showed strategies for managing oral mucosal AEs in this patient population, including the role of dentists in a multidisciplinary team.
Diagnosis & Disease Information
Text Message Reminders Do Not Improve Aromatase Inhibitor Adherence
Investigators suggest more personalized interventions may be needed to improve adherence rates among women with breast cancer receiving AI treatments.
Text Messaging Program Did Not Improve Adherence to Aromatase Inhibitor Therapy in Patients With Breast Cancer
Randomized trial investigated the effect of text messaging reminders on adherence to AI therapy among women with breast cancer.
Improved Pain Scores With Acupuncture for Arthralgia in Breast Cancer Not Clinically Meaningful
In a multicenter study, researchers sought to determine if acupuncture effectively relieved aromatase inhibitor-related joint pain in patients with breast cancer.
Aromatase Inhibitor Use Does Not Increase Risk of Colorectal Cancer
No additional risk of colorectal cancer was noted among women treated with aromatase inhibitors (AIs) following a median follow-up of 2.4 and 2.9 years.
Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
Patients with early-stage breast cancer treated with aromatase inhibitors often experience adverse events that lead to discontinuation. In this phase 3 study, researchers sought to determine if duloxetine could manage these symptoms.
Position Statement on Fracture Risk With AI Therapy in Early-Stage Breast Cancer Updated
Seven interdisciplinary cancer and bone societies released a position statement updating recommendations for limiting bone loss and fracture risk in patients with early-stage breast cancer undergoing treatment with AIs.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Smoking Increases Risk of Adverse Events With Aromatase Inhibitor Therapy for Breast Cancer
Preoperative smoking is associated with increased risk for breast cancer events and distant metastasis in women treated with aromatase inhibitors (AIs). Hampering the utility of AIs, a common treatment for breast cancer, is yet another health risk associated with smoking.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
- Loading...
Loading...
Next post in ASCO 2016 Annual Meeting
Loading... 
Loading...